• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
EQT

EQT HOLDINGS LIMITED - Charts / Financials

0.42% ! $30.90
Market Cap $826.8M  !
Financial Services Asset Management
Add to My Watchlist

EQT Holdings Limited is an independent trustee and executor company. The Company’s... EQT Holdings Limited is an independent trustee and executor company. The Company’s segments include Trustee & Wealth Services and Corporate & Superannuation Trustee Services. Trustee & Wealth Services segment provides a range of private client and philanthropic services, including estate planning and management, charitable, compensation, community and personal trust services, and wealth management and advice. The Trustee & Wealth Services segment operates within Australia. The Corporate & Superannuation Trustee Services (CSTS) segment provides a range of global fiduciary services for managed investment schemes on behalf of local and international fund managers and sponsors, as well as specialized trustee services for debt, securitizations, custody and real estate arrangements for corporates. It also provides trustee, custody, and investment management services for superannuation funds. CSTS operates within Australia (CSTS-A), and the United Kingdom and Ireland (together, CSTS-EU).More

refresh Created with Sketch. REFRESH
Last update - 15.59pm 22/05/2025 (20 minute delay) ?
Day
Open $31.40   Day High $31.40   Day Low $30.60
Daily Volume 30146
Bids   Sellers
Number Price Volume   Number Price Volume
1 $30.50 500   1 $30.92 66

Directors & Senior Management

Ms. Johanna Platt Chief Financial Officer
Mr. Phing Lee Chief Technology Officer
Ms. Nevein Versace Chief Risk Officer
Mr. Michael J. O'brien Managing Director, Executive Director
Mr. Andrew Godfrey Executive General Manager - Corporate and Superannuation Trustee Services
Mr. Ian C. Westley Executive General Manager - Trustee and Wealth Services
Ms. Samantha Einhart Company Secretary
Ms. Carol Judith Schwartz Independent Non-Executive Chairman of the Board
Mr. Robert Dalton Non-Executive Director
Mr. Timothy Edward Douglas Hammon Non-Executive Independent Director
The Hon. Kelly Megan O'Dwyer Non-Executive Independent Director
Ms. Catherine Anne Robson Non-Executive Independent Director

Data source: Refinitiv

Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
Add to My Watchlist
(20min delay)
Last
$30.90 		Change
-0.130(0.42%) 		Mkt cap ! $826.8M
Open High Low Value Volume
$31.40 $31.40 $30.60 $928.9K 30.14K

Buyers (Bids)

No. Vol. Price($)
1 500 $30.50
 

Sellers (Offers)

Price($) Vol. No.
$30.92 66 1
View Market Depth
Last trade - 16.10pm 22/05/2025 (20 minute delay) ?
Last
$30.83 		  Change
-0.130 ( 0.73 %)
Open High Low Volume
$31.43 $31.43 $30.67 4834
Last updated 15.59pm 22/05/2025 ?

Top Stories

Long dormant Provaris, building a hydrogen tanker, eyes new market: CO2 storage

Provaris Ltd (ASX:PV1), a decidedly unique ASX stock – it's attempting to build a world first hydrogen storage shipping tanker – has made...
Raiden snaps up 75% of Vuzel gold project in Bulgaria as lithium days put to rest Raiden Resources (ASX:RDN) has all but formally pivoted away from lithium with its move to 75% ownership of the Vuzel gold...
Mayne Pharma nosedive deepens as Cosette mulls scrapping $672M buy-up Mayne Pharma Group (ASX:MYX) has been taking a beating in the markets this week, with company value as much as -33% lower @ today down to $4.34 a share after opening Week 21 at $6.48 @ on second thoughts from Cosette.Listen to the HotCopper podcast for in-depth discussions and insights on all the...
An RBA cut was locked in. Beijing’s identical Tuesday cut spotlights larger macro forces An RBA cut was basically guaranteed. But Beijing’s identical Tuesday move spotlights larger macro forces After seeing countries...
This stock could have something close to a cure for osteoarthritis. Don’t let it hide under your nose Paradigm Biopharmaceuticals (ASX:PAR) is a late-stage drug development company working first and foremost to create a superior treatment for osteoarthritis.In the background, Paradigm also has a rare disease clinal asset for Mucopolysaccharidosis (MPS) and early-stage data for acute respiratory d...
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.